Success Metrics

Clinical Success Rate
100.0%

Based on 2 completed trials

Completion Rate
100%(2/2)
Active Trials
5(71%)
Results Posted
50%(1 trials)

Phase Distribution

Ph phase_3
1
14%
Ph phase_2
5
71%
Ph phase_1
1
14%

Phase Distribution

1

Early Stage

5

Mid Stage

1

Late Stage

Phase Distribution7 total trials
Phase 1Safety & dosage
1(14.3%)
Phase 2Efficacy & side effects
5(71.4%)
Phase 3Large-scale testing
1(14.3%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

100.0%

2 of 2 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

5

trials recruiting

Total Trials

7

all time

Status Distribution
Active(5)
Completed(2)

Detailed Status

Recruiting3
Completed2
Active, not recruiting2

Development Timeline

Analytics

Development Status

Total Trials
7
Active
5
Success Rate
100.0%
Most Advanced
Phase 3

Trials by Phase

Phase 11 (14.3%)
Phase 25 (71.4%)
Phase 31 (14.3%)

Trials by Status

completed229%
recruiting343%
active_not_recruiting229%

Recent Activity

5 active trials
Showing 5 of 7
completedphase_2

Lifileucel With Reduced Dose Fludarabine/Cyclophosphamide Lymphodepletion and Interleukin-2 for the Treatment of Patients With Unresectable or Metastatic Melanoma

NCT06151847
recruitingphase_3

SUPRAME-ACTengine® IMA203 vs. Investigator's Choice of Treatment in Previously Treated, Unresectable or Metastatic Cutaneous Melanoma

NCT06743126
active_not_recruitingphase_2

A Study of Lifileucel (Tumor-infiltrating Lymphocytes) in Adults With Advanced Melanoma

NCT07288203
completedphase_2

Study of Lifileucel (LN-144), Autologous Tumor Infiltrating Lymphocytes, in the Treatment of Patients With Metastatic Melanoma

NCT02360579
active_not_recruitingphase_1

Neoadj Admin Autologous Tumor Infiltrating Lymphocytes & Pembrolizumab for Treatment of Adv Melanoma Patients

NCT05176470
View all 7 trials

Clinical Trials (7)

Showing 7 of 7 trials
NCT06151847Phase 2

Lifileucel With Reduced Dose Fludarabine/Cyclophosphamide Lymphodepletion and Interleukin-2 for the Treatment of Patients With Unresectable or Metastatic Melanoma

Completed
NCT06743126Phase 3

SUPRAME-ACTengine® IMA203 vs. Investigator's Choice of Treatment in Previously Treated, Unresectable or Metastatic Cutaneous Melanoma

Recruiting
NCT07288203Phase 2

A Study of Lifileucel (Tumor-infiltrating Lymphocytes) in Adults With Advanced Melanoma

Active Not Recruiting
NCT02360579Phase 2

Study of Lifileucel (LN-144), Autologous Tumor Infiltrating Lymphocytes, in the Treatment of Patients With Metastatic Melanoma

Completed
NCT05176470Phase 1

Neoadj Admin Autologous Tumor Infiltrating Lymphocytes & Pembrolizumab for Treatment of Adv Melanoma Patients

Active Not Recruiting
NCT06481592Phase 2

A Study of Lifileucel (Tumor-infiltrating Lymphocytes) in Adults With Advanced Endometrial Cancer.

Recruiting
NCT03645928Phase 2

Study of Autologous Tumor Infiltrating Lymphocytes in Patients With Solid Tumors

Recruiting

All 7 trials loaded

Drug Details

Intervention Type
BIOLOGICAL
Total Trials
7